                </a></li></ul></div><p><strong>Figure 5. </strong></p><a id="article1.body1.sec2.sec5.fig1.caption1.p1" name="article1.body1.sec2.sec5.fig1.caption1.p1"></a><p>Effects of thrombospondin-1 (TSP-1) on angiogenesis and tumor growth in the PPARα-deficient state. (A) First panel demonstrates TSP-1 levels in plasma of PPARα KO and WT mice (ELISA); second panel shows TSP-1 levels in B16-BL6 and B16-F10/GFP tumor lysates at day 30 grown in PPARα WT and KO mice (western blotting); positive CTR for TSP-1, proliferating HUVECs. (B) Western blot analysis of TSP-1 protein in B16-BL6 tumor lysates from PPARα KO mice receiving WT bone marrow (WT BM→KO), and PPARα WT mice receiving KO bone marrow (KO BM→WT); positive CTR for TSP-1, proliferating HUVECs. (C) TSP-1 protein expression is lost in B16-BL6 tumor lysates from PPARα KO mice depleted of granulocytes (GR-1 antibody); positive CTR for TSP-1, proliferating HUVECs. (D) Western blot analysis of TSP-1 expression from isolated leukocytes from tumor-bearing PPARα KO mice; positive CTR, proliferating HUVECs. Levels of β-actin demonstrate protein loading. (E) Effect of TSP-1 neutralizing antibody and control antibody (IgM) on vessel length (n = 6–9 eyes), clock hours (n = 5–9 eyes) and vessel area (n = 5–9 eyes) in the corneal neovascularization assay. (F) B16-BL6 melanoma growth in KO and WT mice treated with TSP-1 neutralizing or control antibody (IgM).</p>
<span>THISISTHEEND
